Wedmont Private Capital Acquires 153 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Wedmont Private Capital increased its holdings in Axon Enterprise, Inc. (NASDAQ:AXON) by 22.8% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 825 shares of the biotechnology company’s stock after buying an additional 153 shares during the period. Wedmont Private Capital’s holdings in Axon Enterprise were worth $469,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of AXON. Brighton Jones LLC bought a new position in Axon Enterprise in the fourth quarter worth approximately $480,000. Kingsview Wealth Management LLC acquired a new position in shares of Axon Enterprise during the fourth quarter worth $212,000. Empowered Funds LLC increased its position in shares of Axon Enterprise by 89.2% during the fourth quarter. Empowered Funds LLC now owns 1,871 shares of the biotechnology company’s stock worth $1,112,000 after purchasing an additional 882 shares in the last quarter. Empirical Finance LLC increased its position in shares of Axon Enterprise by 3.1% during the fourth quarter. Empirical Finance LLC now owns 1,070 shares of the biotechnology company’s stock worth $636,000 after purchasing an additional 32 shares in the last quarter. Finally, Savant Capital LLC increased its position in shares of Axon Enterprise by 5.7% during the fourth quarter. Savant Capital LLC now owns 1,080 shares of the biotechnology company’s stock worth $642,000 after purchasing an additional 58 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Price Performance

NASDAQ AXON opened at $762.66 on Wednesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. The stock’s fifty day moving average price is $652.86 and its 200 day moving average price is $618.42. Axon Enterprise, Inc. has a 1 year low of $279.02 and a 1 year high of $806.64. The company has a market cap of $59.37 billion, a price-to-earnings ratio of 197.07, a PEG ratio of 5.17 and a beta of 1.29.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.07. The company had revenue of $603.63 million for the quarter, compared to the consensus estimate of $585.67 million. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The firm’s revenue for the quarter was up 31.3% compared to the same quarter last year. During the same period last year, the firm earned $1.15 EPS. As a group, equities research analysts forecast that Axon Enterprise, Inc. will post 5.8 earnings per share for the current year.

Insiders Place Their Bets

In other Axon Enterprise news, CFO Brittany Bagley sold 3,400 shares of the stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $700.00, for a total transaction of $2,380,000.00. Following the sale, the chief financial officer now directly owns 131,833 shares of the company’s stock, valued at approximately $92,283,100. This trade represents a 2.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $540.99, for a total value of $5,409,900.00. Following the sale, the chief executive officer now directly owns 3,063,982 shares in the company, valued at $1,657,583,622.18. This represents a 0.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 43,969 shares of company stock valued at $29,909,594. Company insiders own 4.40% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on AXON shares. Needham & Company LLC upped their price target on Axon Enterprise from $600.00 to $750.00 and gave the stock a “buy” rating in a research report on Thursday, May 8th. Bank of America upped their price target on Axon Enterprise from $750.00 to $895.00 and gave the stock a “buy” rating in a research report on Wednesday, June 4th. Craig Hallum downgraded Axon Enterprise from a “buy” rating to a “cautious” rating in a research report on Monday, March 10th. Northcoast Research downgraded Axon Enterprise from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 19th. Finally, Barclays upped their target price on Axon Enterprise from $726.00 to $735.00 and gave the company an “overweight” rating in a research report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $699.55.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.